Cardiac Biomarkers Testing Market by Biomarkers Type, Application and Location of Testing: Global Opportunity Analysis and Industry Forecast, 2021-2030

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.1.1. Biomarker diagnosis vs. conventional diagnosis
3.2. Assessment of key advantages and buying criteria for diagnostic biomarkers
3.2.1. Early diagnosis
3.2.2. Tissue specific diagnosis
3.2.3. Reduce clinical trials
3.2.4. Consistent output
3.3. Key trends impacting the cardiac biomarker testing market
3.3.1. Development of highly sensitive biomarkers for risk stratification
3.3.2. Technological advancements in the cardiac biomarker testing: Serum based biomarkers
3.3.3. Increasing demand for Point-of-care cardiac diagnostics
3.4. Key forces shaping cardiac biomarkers testing market
3.4.1. Top investment pockets
3.5. Top player positioning, 2020
3.6. Value chain analysis
3.7. Government regulations
3.8. Reimbursement issues
3.9. Market dynamics
3.9.1. Drivers
3.9.1.1. Increase in prevalence of cardiovascular diseases
3.9.1.2. Non-invasive Biomarkers66
3.9.1.3. Increase in point-of-care (POC) testing
3.9.2. Restraints
3.9.2.1. Stringent Government Regulation
3.9.2.2. Complex process
3.9.3. Opportunities
3.9.3.1. Personalized medicine
3.9.3.2. Point-of-care (POCT) testing using cardiac biomarker testing
3.9.4. Impact analysis
3.10. Analysis of COVID-19-Impact on the Market

CHAPTER 4: CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Creatine kinase (CK-MB)
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Troponins
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Myoglobin
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Natriuretic peptides (BNP and NT-proBNP)
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Ischemia modified albumin (IMA)
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Other biomarkers type
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

CHAPTER 5: CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Myocardial Infarction
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Congestive heart failure
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Acute coronary syndrome (ACS)
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Atherosclerosis
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Other applications
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country

CHAPTER 6: CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING
6.1. Overview
6.1.1. Market size and forecast
6.2. Point-of-care testing
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Laboratory testing
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

CHAPTER 7: CARDIAC BIOMARKERS TESTING MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U. S.
7.2.2.1.1. U. S. Cardiac biomarkers testing market, by Biomarkers Type
7.2.2.1.2. U. S. Cardiac biomarkers testing market, by application
7.2.2.1.3. U. S. Cardiac biomarkers testing market, by location of testing
7.2.2.2. Canada
7.2.2.2.1. Canada Cardiac biomarkers testing market, by Biomarkers Type
7.2.2.2.2. Canada Cardiac biomarkers testing market, by application
7.2.2.2.3. Canada Cardiac biomarkers testing market, by location of testing
7.2.2.3. Mexico
7.2.2.3.1. Mexico Cardiac biomarkers testing market, by Biomarkers Type
7.2.2.3.2. Mexico Cardiac biomarkers testing market, by application
7.2.2.3.3. Mexico Cardiac biomarkers testing market, by location of testing
7.2.3. North America market size and forecast, by Biomarkers Type
7.2.4. North America market size and forecast, by application
7.2.5. North America market size and forecast, by location of testing
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. UK
7.3.2.1.1. UK Cardiac biomarkers testing market, by Biomarkers Type
7.3.2.1.2. UK Cardiac biomarkers testing market, by application
7.3.2.1.3. UK Cardiac biomarkers testing market, by location of testing
7.3.2.2. France
7.3.2.2.1. France Cardiac biomarkers testing market, by Biomarkers Type
7.3.2.2.2. France Cardiac biomarkers testing market, by application
7.3.2.2.3. France Cardiac biomarkers testing market, by location of testing
7.3.2.3. Germany
7.3.2.3.1. Germany Cardiac biomarkers testing market, by Biomarkers Type
7.3.2.3.2. Germany Cardiac biomarkers testing market, by application
7.3.2.3.3. Germany Cardiac biomarkers testing market, by location of testing
7.3.2.4. Rest of Europe
7.3.2.4.1. Rest of Europe Cardiac biomarkers testing market, by Biomarkers Type
7.3.2.4.2. Rest of Europe Cardiac biomarkers testing market, by application
7.3.2.4.3. Rest of Europe Cardiac biomarkers testing market, by location of testing
7.3.3. Europe market size and forecast, by Biomarkers Type
7.3.4. Europe market size and forecast, by application
7.3.5. Europe market size and forecast, by location of testing
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. China
7.4.2.1.1. China Cardiac biomarkers testing market, by Biomarkers Type
7.4.2.1.2. China Cardiac biomarkers testing market, by application
7.4.2.1.3. China Cardiac biomarkers testing market, by location of testing
7.4.2.2. India
7.4.2.2.1. India Cardiac biomarkers testing market, by Biomarkers Type
7.4.2.2.2. India Cardiac biomarkers testing market, by application
7.4.2.2.3. India Cardiac biomarkers testing market, by location of testing
7.4.2.3. Australia
7.4.2.3.1. Australia Cardiac biomarkers testing market, by Biomarkers Type
7.4.2.3.2. Australia Cardiac biomarkers testing market, by application
7.4.2.3.3. Australia Cardiac biomarkers testing market, by location of testing
7.4.2.4. Japan
7.4.2.4.1. Japan Cardiac biomarkers testing market, by Biomarkers Type
7.4.2.4.2. Japan Cardiac biomarkers testing market, by application
7.4.2.4.3. Japan Cardiac biomarkers testing market, by location of testing
7.4.2.5. Rest of Asia-Pacific
7.4.2.5.1. Rest of Asia-Pacific Cardiac biomarkers testing market, by Biomarkers Type
7.4.2.5.2. Rest of Asia-Pacific Cardiac biomarkers testing market, by application
7.4.2.5.3. Rest of Asia-Pacific Cardiac biomarkers testing market, by location of testing
7.4.3. Asia-Pacific market size and forecast, by Biomarkers Type
7.4.4. Asia-Pacific market size and forecast, by application
7.4.5. Asia-Pacific market size and forecast, by location of testing
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Latin America
7.5.2.1.1. Latin America Cardiac biomarkers testing market, by Biomarkers Type
7.5.2.1.2. Latin America Cardiac biomarkers testing market, by application
7.5.2.1.3. Latin America Cardiac biomarkers testing market, by location of testing
7.5.2.2. Middle East
7.5.2.2.1. Middle East Cardiac biomarkers testing market, by Biomarkers Type
7.5.2.2.2. Middle East Cardiac biomarkers testing market, by application
7.5.2.2.3. Middle East Cardiac biomarkers testing market, by location of testing
7.5.2.3. Africa
7.5.2.3.1. Africa Cardiac biomarkers testing market, by Biomarkers Type
7.5.2.3.2. Africa Cardiac biomarker testing market, by application
7.5.2.3.3. Africa Cardiac biomarkers testing market, by location of testing
7.5.3. LAMEA market size and forecast, by Biomarkers Type
7.5.4. LAMEA market size and forecast, by application
7.5.5. LAMEA market size and forecast, by location of testing

CHAPTER 8: COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. BECTON, DICKINSON AND COMPANY
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. BIOMERIEUX, INC.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. BIO-RAD LABORATORIES, INC.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. DANAHER CORPORATION
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. F. HOFFMANN-LA ROCHE LTD.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. PERKINELMER INC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. SIEMENS AG
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. THERMO FISHER SCIENTIFIC, INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. TOSOH CORPORATION
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performanceLIST OF TABLES
TABLE 01. CONVENTIONAL DIAGNOSTICS VERSUS DIAGNOSTIC BIOMARKER TECHNIQUES
TABLE 02. GLOBAL CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKES TYPE, 2020-2030 ($MILLION)
TABLE 03. CARDIAC BIOMARKERS TESTING MARKET FOR CREATINE KINASE(CK-MB), BY REGION,
2020-2030 ($MILLION)
TABLE 04. CARDIAC BIOMARKERS TESTING MARKET FOR TROPONINS, BY REGION, 2020-2030 ($MILLION)
TABLE 05. CARDIAC BIOMARKERS TESTING MARKET FOR MYOGLOBIN, BY REGION, 2020-2030 ($MILLION)
TABLE 06. CARDIAC BIOMARKERS TESTING MARKET FOR NATRIURETIC PEPTIDES (BNP AND NT-PROBNP),
BY REGION, 2020-2030 ($MILLION)
TABLE 07. CARDIAC BIOMARKERS TESTING MARKET FOR ISCHEMIA MODIFIED ALBUMIN (IMA), BY REGION,
2020-2030 ($MILLION)
TABLE 08. CARDIAC BIOMARKERS TESTING MARKET FOR OTHERS BIOMARKERS TYPE, BY REGION,
2020-2030 ($MILLION)
TABLE 09. CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 10. CARDIAC BIOMARKERS TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION,
2020-2030 ($MILLION)
TABLE 11. CARDIAC BIOMARKERS TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION,
2020-2030 ($MILLION)
TABLE 12. CARDIAC BIOMARKERS TESTING MARKET FOR ACUTE CORONARY SYNDROME (ACS), BY REGION,
2020-2030 ($MILLION)
TABLE 13. CARDIAC BIOMARKERS TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION,
2020-2030 ($MILLION)
TABLE 14. CARDIAC BIOMARKERS TESTING MARKET FOR OTHER APPLICATIONS, BY REGION,
2020-2030 ($MILLION)
TABLE 15. CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 ($MILLION)
TABLE 16. CARDIAC BIOMARKERS TESTING MARKET FOR POINT OF CARE TESTING (POCT), BY REGION,
2020-2030 ($MILLION)
TABLE 17. CARDIAC BIOMARKERS TESTING MARKET FOR LABORARTORY TESTING, BY REGION,
2020-2030 ($MILLION)
TABLE 18. CARDIAC BIOMARKERS TESTING MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 19. NORTH AMERICA CARDIAC BIOMARKERS TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 20. U.S. CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020-2030 ($MILLION)
TABLE 21. U.S. CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 22. U.S. CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 ($MILLION)
TABLE 23. CANADA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKES TYPE, 2020-2030 ($MILLION)
TABLE 24. CANADA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 25. CANADA CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 ($MILLION)
TABLE 26. MEXICO CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020-2030 ($MILLION)
TABLE 27. MEXICO CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 28. MEXICO CARDIAC BIOMARKERS TESTING MARKET, BYLOCATION OF TESTING, 2020-2030 ($MILLION)
TABLE 29. NORTH AMERICA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE,
2020-2030 ($MILLION)
TABLE 30. NORTH AMERICA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 31. NORTH AMERICA CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING,
2020-2030 ($MILLION)
TABLE 32. EUROPE CARDIAC BIOMARKER TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 33. UK CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKET TYPE, 2020-2030 ($MILLION)
TABLE 34. UK CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 35. UK CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 ($MILLION)
TABLE 36. FRANCE CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020-2030 ($MILLION)
TABLE 37. FRANCE CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 38. FRANCE CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 ($MILLION)
TABLE 39. GERMANY CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020-2030 ($MILLION)
TABLE 40. GERMANY CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 41. GERMANY CARDIAC BIOMARKERS TESTING MARKET, BYLOCATION OF TESTING,
2020-2030 ($MILLION)
TABLE 42. REST OF EUROPE CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE,
2020-2030 ($MILLION)
TABLE 43. REST OF EUROPE CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 44. REST OF EUROPE CARDIAC BIOMARKER TESTING MARKET, BYLOCATION OF TESTING,
2020-2030 ($MILLION)
TABLE 45. EUROPE CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKET TYPE, 2020-2030 ($MILLION)
TABLE 46. EUROPE CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 47. EUROPE CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 ($MILLION)
TABLE 48. ASIA-PACIFIC CARDIAC BIOMARKERS TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 49. CHINA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020-2030 ($MILLION)
TABLE 50. CHINA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 51. CHINA CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 ($MILLION)
TABLE 52. INDIA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020-2030 ($MILLION)
TABLE 53. INDIA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 54. INDIA CARDIAC BIOMARKERS TESTING MARKET, BYLOCATION OF TESTING, 2020-2030 ($MILLION)
TABLE 55. AUSTRALIA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020-2030 ($MILLION)
TABLE 56. AUSTRALIA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 57. AUSTRALIA CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING,
2020-2030 ($MILLION)
TABLE 58. JAPAN CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020-2030 ($MILLION)
TABLE 59. JAPAN CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 60. JAPAN CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 ($MILLION)
TABLE 61. REST OF ASIA-PACIFIC CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE,
2020-2030 ($MILLION)
TABLE 62. REST OF ASIA-PACIFIC CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION,
2020-2030 ($MILLION)
TABLE 63. REST OF ASIA-PACIFIC CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING,
2020-2030 ($MILLION)
TABLE 64. ASIA-PACIFIC CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE,
2020-2030 ($MILLION)
TABLE 65. ASIA-PACIFIC CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 66. ASIA-PACIFIC CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING,
2020-2030 ($MILLION)
TABLE 67. LAMEA CARDIAC BIOMARKERS TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 68. LATIN AMERICA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKETS TYPE,
2020-2030 ($MILLION)
TABLE 69. LATIN AMERICA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 70. LATIN AMERICA CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING,
2020-2030 ($MILLION)
TABLE 71. MIDDLE EAST CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE,
2020-2030 ($MILLION)
TABLE 72. MIDDLE EAST CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 73. MIDDLE EAST CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING,
2020-2030 ($MILLION)
TABLE 74. AFRICA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020-2030 ($MILLION)
TABLE 75. AFRICA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 76. AFRICA CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 ($MILLION)
TABLE 77. LAMEA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020-2030 ($MILLION)
TABLE 78. LAMEA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 79. LAMEA CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 ($MILLION)
TABLE 80. ABBOTT: COMPANY SNAPSHOT
TABLE 81. ABBOTT: OPERATING SEGMENTS
TABLE 82. ABBOTT: PRODUCT PORTFOLIO
TABLE 83. BD: COMPANY SNAPSHOT
TABLE 84. BD: OPERATING SEGMENTS
TABLE 85. BD: PRODUCT PORTFOLIO
TABLE 86. BIOMÉRIEUX, INC.: COMPANY SNAPSHOT
TABLE 87. BIOMÉRIEUX, INC.: OPERATING SEGMENTS
TABLE 88. BIOMÉRIEUX: PRODUCT PORTFOLIO
TABLE 89. BIO-RAD: COMPANY SNAPSHOT
TABLE 90. BIO-RAD: OPERATING SEGMENTS
TABLE 91. BIO RAD: PRODUCT PORTFOLIO
TABLE 92. DANAHER: COMPANY SNAPSHOT
TABLE 93. DANAHER: OPERATING SEGMENTS
TABLE 94. DANAHER: PRODUCT PORTFOLIO
TABLE 95. ROCHE: COMPANY SNAPSHOT
TABLE 96. ROCHE: OPERATING SEGMENTS
TABLE 97. ROCHE: PRODUCT PORTFOLIO
TABLE 98. PERKINELMER: COMPANY SNAPSHOT
TABLE 99. PERKINELMER: OPERATING SEGMENTS
TABLE 100. PERKINELMER PRODUCT PORTFOLIO
TABLE 101. SIEMENS: COMPANY SNAPSHOT
TABLE 102. SIEMENS: PRODUCT SEGMENTS
TABLE 103. SIEMENS: PRODUCT PORTFOLIO
TABLE 104. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 105. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 106. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 107. TOSOH: COMPANY SNAPSHOT
TABLE 108. TOSOH: OPERATING SEGMENTS
TABLE 109. TOSOH: PRODUCT PORTFOLIOLIST OF FIGURES
FIGURE 01. CARDIAC BIOMARKER TESTING MARKET SEGMENTATION
FIGURE 02. HIGH BARGAINING POWER OF BUYERS
FIGURE 03. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04. MODERATE THREAT OF SUBSTITUTION
FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
FIGURE 06. MODERATE COMPETITVE RIVARLY
FIGURE 07. TOP INVESTMENT POCKETS, 2020
FIGURE 08. TOP PLAYER POSITIONING, 2020
FIGURE 09. VALUE CHAIN ANALYSIS OF GLOBAL CARDIAC BIOMARKERS TESTING
FIGURE 10. IMPACT ANALYSIS
FIGURE 11. COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR CREATINE KINASE
(CK-MB), BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR TROPONINS,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR MYOGLOBIN,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR NATRIURETIC PEPTIDES
(BNP AND NT-PROBNP), BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR ISCHEMIA MODIFIED
ALBUMIN (IMA), BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR OTHER BIOMARKERS
TYPE, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR MYOCARDIAL INFARCTION,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18. COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR CONGESTIVE HEART
FAILURE, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19. COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR ACUTE CORONARY
SYNDROME (ACS), BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20. COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR ATHEROSCLEROSIS,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21. COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22. COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FORPOINT OF CARE OF
TESTING (POCT), BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23. COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR LABORATORY TESTING,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24. ABBOTT: NET SALES, 2018-2020 ($MILLION)
FIGURE 25. ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26. ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 27. BD: NET SALES, 2018-2020 ($MILLION)
FIGURE 28. BD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29. BD: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 30. BIOMÉRIEUX, INC.: REVENUE, 2018-2020 ($MILLION)
FIGURE 31. BIOMÉRIEUX: REVENUE SHARE BYSEGMENT, 2020 (%)
FIGURE 32. BIOMÉRIEUX: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 33. BIO-RAD: NET SALES, 2018-2020 ($MILLION)
FIGURE 34. BIO-RAD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 35. BIO-RAD: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 36. DANAHER: NET SALES, 2018-2020 ($MILLION)
FIGURE 37. DANAHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 38. DANAHER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 39. ROCHE: NET SALES, 2018-2020 ($MILLION)
FIGURE 40. ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 41. ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42. PERKINELMER: NET SALES, 2018-2020 ($MILLION)
FIGURE 43. PERKINELMER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 44. PERKINELMER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 45. SIEMENS: NET SALES, 2018-2020 ($MILLION)
FIGURE 46. SIEMENS: REVENUE SHARE BY PRODUCT SEGMENT, 2020 (%)
FIGURE 47. SIEMENS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 48. THERMO FISHER SCIENTIFIC: REVENUE, 2018-2020 ($MILLION)
FIGURE 49. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 50. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 51. TOSOH: NET SALES, 2018-2020 ($MILLION)
FIGURE 52. TOSOH: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 53. TOSOH: REVENUE SHARE BY REGION, 2020 (%)

Companies Mentioned

• Abbott Laboratories
• Becton
• Dickinson Company
• bioMerieux Inc.
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• PerkinElmer Inc.
• Siemens AG
• Thermo Fisher Scientific Inc.
• Tosoh Corporation.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.